World's most powerful X-ray laser reveals drug target for sleeping sickness
Using the world's most powerful X-ray laser, an international team of scientists has revealed the three dimensional structure of a key enzyme that enables the single-celled parasite that causes African trypanosomiasis (or sleeping sickness) in humans.
With the elucidation of the 3D structure of the cathepsin B enzyme, it will be possible to design new drugs to inhibit the parasite (Trypanosoma brucei) that causes sleeping sickness, leaving the infected human unharmed.
The research team, including several ASU scientists, is led by the German Electron Synchrotron (DESY) scientist Henry Chapman from the Center of Free-Electron Laser Science (CFEL), professor Christian Betzel from the University of Hamburg and Lars Redecke from the SIAS joint Junior Research Group at the Universities of Hamburg and Lubeck.
"This is the first new biological structure solved with a free-electron laser," said Chapman of the development.
"These images of an enzyme, which is a drug target for sleeping sickness, are the first results from our new 'diffract-then-destroy' snapshot X-ray laser method to show new biological structures which have not been seen before," explained John Spence, ASU Regents' Professor of Physics.
"The work was led by the DESY group and used the Linac Coherent Light Source at the U.S. Department of Energy's SLAC National Accelerator Laboratory," he stated.
Transferred to its mammalian host by the bite of the tsetse fly, the effects of the parasite are almost always fatal if treatment is not received. The sleeping sickness parasite threatens more than 60 million people in sub-Saharan Africa and annually kills an estimated 30,000 people. Current drug treatments are not well tolerated, cause serious side effects and the parasites are becoming increasingly drug resistant.
An additional difficulty includes the fact that the cathepsin B enzyme is also found in humans and all mammals. However the discovery of the enzyme's 3D structure has enabled the researchers to pinpoint distinctive structural differences between the human and the parasite's form of the enzyme. Subsequent drug targets can selectively block the parasite's enzyme, leaving the patient's intact.
They reported their findings this week in Science.